Organogenesis price target raised to $6 from $4 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Organogenesis to $6 from $4 and keeps a Buy rating on the shares. The analyst cites the ceiling payment rates updated in Medicare Part B ASP drug pricing but notes that while the company’s PuraPly XT pricing is being impacted from LCD dynamics, the management’s reinstated guidance “matters more”.